Skip to main
EKSO

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc. reported a notable recovery in its financial performance for the third quarter of 2025, with total revenues reaching $4.22 million, reflecting a year-over-year growth of 105% compared to $2.06 million in the previous quarter. Additionally, the company experienced a significant improvement in gross margins, rising to 60.3%, up from 39.8% in the prior quarter. This positive trajectory in revenue and profitability, along with a potential merger announcement, indicates a strong operational rebound and strategic positioning within the exoskeleton technology market.

Bears say

Ekso Bionics Holdings Inc experienced a revenue miss in prior quarters, attributed to two significant order delays from enterprise sales that collectively impacted revenue by $1.5 million. For the third quarter of 2025, the company reported revenues of $4.23 million alongside a net loss of $0.54 per share, which highlights ongoing financial challenges despite slightly exceeding consensus expectations. The downgrade in rating reflects concerns about the company's ability to secure timely orders, signaling potential instability in its sales pipeline and overall performance.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.